Nurix Therapeutics Inc
For the period ended Nov 30, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
NRIX$15.88-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Year Ended November 30, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities | ||
| Net loss | $(143,948) | $(180,360) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 7,533 | 5,349 |
| Stock-based compensation | 33,673 | 28,131 |
| Net amortization (accretion) of premium (discount) on marketable securities | (5,421) | 426 |
| Loss on disposal of property and equipment | 556 | 9 |
| Amortization of operating lease right-of-use assets | 6,121 | 5,459 |
| Other | — | 201 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | — | 6,000 |
| Prepaid expenses and other assets | 2,139 | (1,094) |
| Accounts payable | 1,614 | 85 |
| Deferred revenue | 19,513 | (26,627) |
| Operating lease liabilities | (6,268) | (4,871) |
| Accrued expenses and other liabilities | 3,123 | 7,485 |
| Net cash used in operating activities | (81,365) | (159,807) |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (246,334) | (239,366) |
| Maturities of marketable securities | 323,036 | 278,808 |
| Purchases of property and equipment | (8,401) | (12,244) |
| Net cash provided by investing activities | 68,301 | 27,198 |
| Cash flows from financing activities | ||
| Proceeds from issuances of pre-funded warrants, net of issuance costs | — | 94,759 |
| Proceeds from issuances of common stock in equity financing, net of issuance costs | — | 19,400 |
| Proceeds from exercise of stock options and pre-funded warrants | 988 | 1,078 |
| Proceeds from issuance under employee stock purchase plan | 2,229 | 1,955 |
| Net cash provided by financing activities | 3,217 | 117,192 |
| Net decrease in cash, cash equivalents and restricted cash | (9,847) | (15,417) |
| Cash, cash equivalents and restricted cash at beginning of period | 65,375 | 80,792 |
| Cash, cash equivalents and restricted cash at end of period | $55,528 | $65,375 |
| Supplemental disclosures of non-cash investing and financing activities: | ||
| Additions to property and equipment included in accounts payable and accrued expenses and other liabilities | $632 | $1,373 |
| Capitalized stock-based compensation related to internal-use software development | $74 | $69 |
| Right-of-use assets recognized in exchange for lease obligations | $23,995 | $5,068 |
| Vesting of early exercised stock options | $117 | $145 |
| Deferred issuance costs recognized related to equity financing | $— | $72 |
| As of November 30, | ||
|---|---|---|
| 2023 | 2022 | |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $54,627 | $64,474 |
| Restricted cash | 901 | 901 |
| Cash, cash equivalents and restricted cash | $55,528 | $65,375 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.